REDUCED T3 DEIODINATION BY THE HUMAN HEPATOBLASTOMA CELL-LINE HEPG2 CAUSED BY DEFICIENT T3 SULFATION

被引:8
作者
VANSTRALEN, PGJ [1 ]
VANDERHOEK, HJ [1 ]
DOCTER, R [1 ]
DEJONG, M [1 ]
KRENNING, EP [1 ]
LIM, CF [1 ]
HENNEMANN, G [1 ]
机构
[1] ACAD HOSP ROTTERDAM DIJKZIGT,DEPT NUCL MED,ROTTERDAM,NETHERLANDS
关键词
HEPG2; T3; SULFATE; HOMOGENATE; (RAT); (HUMAN LIVER);
D O I
10.1016/0304-4165(93)90086-N
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Type I deiodination of T3 sulfate occurs at a V(max) that is 30-fold higher as compared to T3, both in rat and in human liver homogenates. We now present data showing lack of T3 deiodination by a human liver derived hepatoblastoma cell line, HepG2, caused by deficient T3 sulfation. Cellular entry of T3 was assessed by its nuclear binding after whole cell incubation. In spite of the presence of type I deiodinase, as confirmed by T4 and rT3 deiodination in homogenates, no deiodination of T3 could be detected. Since HepG2 cell homogenates also deiodinated chemically synthesized T3 sulfate (T3S) and inhibition of type I deiodination by propylthiouracil (PTU) did not cause T3S accumulation in whole cell incubations, we conclude that (i) HepG2 cells show reduced T3 deiodination caused by deficient T3 sulfation, and (ii) sulfation of T3 is an obligatory step prior to hepatic deiodination.
引用
收藏
页码:114 / 118
页数:5
相关论文
共 22 条
[1]   THYROXINE UPTAKE BY HUMAN HEPATOMA-CELLS FROM SERUM OF PATIENTS SUBMITTED TO LONG-TERM THYROXINE SUPPRESSIVE THERAPY [J].
BARTALENA, L ;
MARTINO, E ;
FALCONE, M ;
PACCHIAROTTI, A ;
PINCHERA, A .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1988, 11 (09) :629-635
[2]  
BLONDEAU JP, 1988, J BIOL CHEM, V263, P2685
[3]   INDUCTION OF DRUG-METABOLIZING ENZYMES IN HUMAN-LIVER CELL-LINE HEP-G2 [J].
DAWSON, JR ;
ADAMS, DJ ;
WOLF, CR .
FEBS LETTERS, 1985, 183 (02) :219-222
[4]   ACTIVE-TRANSPORT OF IODOTHYRONINES INTO HUMAN CULTURED FIBROBLASTS [J].
DOCTER, R ;
KRENNING, EP ;
BERNARD, HF ;
HENNEMANN, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 65 (04) :624-628
[5]   INHIBITION OF UPTAKE OF THYROID-HORMONE INTO RAT HEPATOCYTES BY PREINCUBATION WITH N-BROMOACETYL-3,3',5-TRIIODOTHYRONINE [J].
DOCTER, R ;
KRENNING, EP ;
BERNARD, HF ;
VISSER, TJ ;
HENNEMANN, G .
ENDOCRINOLOGY, 1988, 123 (03) :1520-1525
[6]  
DOCTER R, 1990, THYROID GLAND, P233
[7]   FLUOROMETRIC QUANTIFICATION OF DNA IN CELLS AND TISSUE [J].
DOWNS, TR ;
WILFINGER, WW .
ANALYTICAL BIOCHEMISTRY, 1983, 131 (02) :538-547
[8]   THYROID-HORMONE TRANSPORT IN A HUMAN GLIOMA CELL-LINE [J].
GONCALVES, E ;
LAKSHMANAN, M ;
PONTECORVI, A ;
ROBBINS, J .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1990, 69 (2-3) :157-165
[9]   EVIDENCE FOR AN ACTIVE STEP IN THYROID-HORMONE TRANSPORT TO NUCLEI - DRUG-INHIBITION OF L-I-125-TRIIODOTHYRONINE BINDING TO NUCLEAR RECEPTORS IN RAT PITUITARY-TUMOR CELLS [J].
HALPERN, J ;
HINKLE, PM .
ENDOCRINOLOGY, 1982, 110 (03) :1070-1072
[10]   CARRIER-MEDIATED TRANSPORT OF THYROID-HORMONE INTO RAT HEPATOCYTES IS RATE-LIMITING IN TOTAL CELLULAR UPTAKE AND METABOLISM [J].
HENNEMANN, G ;
KRENNING, EP ;
POLHUYS, M ;
MOL, JA ;
BERNARD, BF ;
VISSER, TJ ;
DOCTER, R .
ENDOCRINOLOGY, 1986, 119 (04) :1870-1872